Cognition in Parkinson's Disease

Dr. Nandakumar Narayanan is Associate Professor & Associate Director of the Iowa Neuroscience Institute, University of Iowa. The specific problem of his research is cognitive dysfunction in Parkinsons disease. His current research focuses on the influence of dopamine on prefrontal networks controlling cognitive behaviors such as timing and performance monitoring. His research combines ensemble recording from populations of neurons in awake, behaving animals with specific manipulations using techniques such as optogenetic stimulation, targeted pharmacology, or selective genetic disruption with RNA interference. HIs research hopes to identify new treatment strategies that can be translated to a clinical setting. Roger L. Albin, MD, is a professor of neurology and co-director of the Movement Disorders Clinic in the Department of Neurology in the University of Michigan Medical School. In addition, he serves as chief of neuroscience research at the VA Ann Arbor Healthcare System Geriatric Research Education and Clinical Center.Dr. Albin joined the University of Michigan faculty in 1988 as an instructor in the Department of Neurology. He was promoted to assistant professor in 1989; associate professor in 1994; and achieved his current rank of full professor in 2000.After completing his undergraduate degree at Oberlin College in Ohio, Dr. Albin earned his medical degree from the University of Pittsburgh School of Medicine in 1982, and completed his residency at the University of Michigan in 1986. He also completed a movement disorders fellowship in 1988 under Drs. Anne Young and John Penney.His clinical and research interests include the underlying neurobiologic causes of the clinical features of movement disorders, basal ganglia structure and function, Parkinson's disease, Tourette syndrome, dementias, dystonias and Huntington's disease. His laboratory is pursuing work on basic mechanisms of neurodegeneration in Huntington disease using mouse genetic models. Dr. Albin also has participated in neuroprotective clinical trials for both Huntington's disease and Parkinson's disease.The present focus of Dr. Albin's group is uncovering the basis for non-motor (sleep disorders, depression, dementia, autonomic dysfunction) problems in Parkinson's disease. He is very interested in applying positron emission tomography (PET) imaging methods to improve diagnosis of dementing disorders like Alzheimer's disease. The hope is that understanding how specific brain alterations cause specific clinical features will lead to improved treatments.Dr. Albin currently serves as a site investigator for the National Institutes of Health (NIH) Exploratory Trials in Parkinson disease (NET-PD) initiative. His work is supported by grants from the NIH, the Michael J. Fox Foundation and the High Q Foundation.A member of the American Academy of Neurology, the American Association for the Advancement of Science, the American Neurologic Association, and the Society for Neuroscience, Dr. Albin currently serves on the editorial boards of Experimental Neurology, Neurology and Neurobiology of Disease.

• Defining the problem1. IntroductionN. S. Narayanan and Roger L. Albin2. The epidemiology of cognitive function in Parkinson's diseaseCaroline M Tanner and Meredith A. Bock3. Neuropsychology of Parkinson’s diseaseSteven Anderson and Cole Toovey4. Cognitive dysfunction and neuropsychiatric aspects of Parkinson’sdiseaseLaura Marsh and Gabriela AustgenClinical characteristics5. Cognition in Prodromal Parkinson’s diseaseInga Liepelt-Scarfone, Anja Ophey and Elke Kalbe6. Real-life consequences of cognitive dysfunction in Parkinson’s diseaseErgun Y. Uc and Kevin Kay7. Cognitive control and Parkinson’s diseaseJames F. Cavanagh, Sarah Pirio Richardson and Sephira Ryman8. Speech dysfunction, cognition, and Parkinson’s diseaseJeremy Greenlee, Kris Tjaden, Andrea Rohl, Stephanie Gutierrez and Angela C. RobertsPathophysiology9. Neuropathology and Cognition in Parkinson’s diseaseDavid J. Irwin and David Coughlin10. Genetics of cognitive dysfunction in Parkinson’s diseaseRoy Alcalay and Adina Wise11. Animal models of action control and cognitive dysfunction in Parkinson’s diseaseBernard Balleine12. Neuroimaging approaches to cognition in Parkinson’s diseaseKathleen L. Poston, Leila Kouhsari and Christina YoungCircuit mechanisms13. Functional neuroanatomy of cognition in Parkinson’s diseaseNader Pouratian, Timothy J. Florence, Cody Wolfe and Koorosh Mirpour14. Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease'Roshan Cools, Jorryt Tichelaar, Rick Helmich, Bas Bloem, Rianne Esselink, Katrijn Smulders and Monique Timmer15. Cholinergic Systems, Attentional-Motor Integration, and Cognitive Control in Parkinson DiseaseRoger L. Albin, Martin Sarter, Sygrid van der Zee, Teus van Laar, Cindy Lustig, Martijn Muller and Nicolaas I.L.J Bohnen16. Cognition and serotonin in Parkinson’s diseasePhilippe Huot, Sebastien Belliveau, Imane Frouni and Cynthia KwanTowards therapies17. Caring for patients with cognitive dysfunction, fluctuations and dementia caused by Parkinson’s DiseaseGeorgina Aldridge, Oday Halhouli and Qiang Zhang18. Neuromodulation of cognition in Parkinson’s diseaseN. S. Narayanan, Rachel Cole, Derrick Okine and Brooke Yeager19. The way forward for cognition and Parkinson's diseaseN. S. Narayanan and Roger L. Albin